Tobacco Documents Online

Analytical Method Status Report and Revised Philip Morris/Covance Project Tearn Page 1 of 1 1 04~ 1 114 1 WJ(tir 1 Q8 1 xI +. From; To: Cc: Subject: Sent: -W I? Jill Schultz [SMTP:jilLschultz@Covance.Com] Oey, Jan Tricker, Anthony; von Holt, Klaus; Nelson, Bettie L; Kinser, Robin D.; Walk, Roger A. Analytical Method Status Report and Revised Philip Morris/Covance Project Team 11/30/00 5:43 PM Importance: Dear Dr. Oey, Attached is a copy of the analytical method development/validation status report. We are eager to move forward on each of the methods and are awaiting the signed LOI. Please review the action items listed under current status for each biomarker. I have also attached a revised copy of the team contact list as there have been some additions/deletions. The draft protoco] and questionnaire will be available for your review I approximately I week following receipt of the signed LOt. Please do not hesitate to contact me if you have any questions or concerns. Thank you, Jill M. Schultz Drug Development Consultant Strategic Product Development Phone: 608-242-2712, ext. 2354 Fax: 608-245-7001 j ill.schultz@covance.com Confidentiality Notice: This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance I, upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, ', please reply to the sender, so that we can arrange '. for proper delivery, and then please delete the message j from your inbox. Thank you. n PMAnalytical.doc ncv pm team.doc Normal .../read.asp?command=open&obj=00000000E3E328F94537D2119DD700805F8B9540 01-Dec-2000